Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.36 |
| ▸ | CTSL | P07711 | 3/20 | 0.34 |
| ▸ | CTSB | P07858 | 2/20 | 0.34 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
| ▸ | CTSC | P53634 | 1/20 | 0.34 |
| ▸ | PPID | Q08752 | 1/20 | 0.34 |
| ▸ | CAPN9 | O14815 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.33 |
| ▸ | CTSG | P08311 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 2/20 | 0.32 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.32 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.32 |
| ▸ | METAP2 | P50579 | 2/20 | 0.32 |
| ▸ | METAP1 | P53582 | 2/20 | 0.32 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.32 |
| ▸ | CAD | P27708 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18452348 | 1.00 | L3MBTL1 (0.39) | L3MBTL1KMT2APOLBNOD1CTSL | |
| SCHEMBL20465429 | 1.00 | L3MBTL1 (0.39) | L3MBTL1KMT2APOLBNOD1CTSL | |
| SCHEMBL20465440 | 0.97 | CTSL (0.39) | L3MBTL1KMT2APOLBNOD1CTSL | |
| SCHEMBL18452352 | 0.97 | CTSL (0.39) | L3MBTL1KMT2APOLBNOD1CTSL | |
| SCHEMBL18451208 | 0.88 | CTSL (0.32) | CTSLCTSBCTSSCTSCANPEP | |
| SCHEMBL20465427 | 0.88 | CTSL (0.32) | CTSLCTSBCTSSCTSCANPEP | |
| SCHEMBL20468520 | 0.88 | L3MBTL1 (0.39) | L3MBTL1KMT2APOLBNOD1CTSL | |
| SCHEMBL20465422 | 0.88 | L3MBTL1 (0.43) | L3MBTL1KMT2APOLBNOD1METAP2 | |
| SCHEMBL18451341 | 0.88 | L3MBTL1 (0.43) | L3MBTL1KMT2APOLBNOD1METAP2 | |
| SCHEMBL30919316 | 0.88 | NOD1 (0.38) | L3MBTL1KMT2APOLBNOD1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250177367-A1 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION | 2025-06-05 | — | — | US | claimed |
| WO-2025073968-A1 | COMBINATION OF ROGINOLISIB WITH A MALT1-GLS INHIBITOR | IONCTURA SA (CH) | 2025-04-10 | — | — | WO | claimed |
| CN-119677539-A | Combination therapy for modulating lipid production | 俄亥俄州创新基金会 | 2025-03-21 | — | — | CN | claimed |
| EP-4489865-A2 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | Ohio State Innovation Foundation (US) | 2025-01-15 | — | — | EP | claimed |
| WO-2023172669-A9 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION (US) | 2024-08-02 | — | — | WO | claimed |
| WO-2023172669-A2 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION (US) | 2023-09-14 | — | — | WO | claimed |
| CN-116510024-A | Composition, preparation method and application thereof | 上海复东生物医药有限责任公司 | 2023-08-01 | — | — | CN | claimed |
| EP-4709372-A1 | SMALL MOLECULE INHIBITORS OF GLUTAMINASE | Leal Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4680215-A1 | COMPOSITIONS AND METHODS FOR AMELIORATING ADVERSE EFFECTS OF THERAPIES | MDX Management LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4658641-A1 | NOVEL COMPOUNDS THAT CAN BE USED AS THERAPEUTIC AGENTS | Xeniom GmbH (DE) | 2025-12-10 | — | — | EP | disclosed |
| US-20250177367-A1 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | OHIO STATE INNOVATION FOUNDATION | 2025-06-05 | — | — | US | disclosed |
| US-20250161287-A1 | METHODS, COMPOSITIONS, AND COMBINATIONS FOR PREVENTING OR TREATING CANCER RECURRENCE | VUJA DE SCIENCES INC (US) | 2025-05-22 | — | — | US | disclosed |
| CN-119792538-A | Novel therapeutic methods for glioblastoma | 昆明医科大学第二附属医院 | 2025-04-11 | — | — | CN | disclosed |
| CN-116510024-A | Composition, preparation method and application thereof | 上海复东生物医药有限责任公司 | 2023-08-01 | — | — | CN | disclosed |
| WO-2023085771-A1 | ANTICANCER COMPOSITION COMPRISING METABOLIC ANTICANCER DRUG | 주식회사 노암 | 2023-05-19 | — | — | WO | disclosed |
| WO-2023081775-A1 | COMBINATION INHIBITORS FOR TREATING FIBROSIS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023081832-A1 | METHODS FOR PREVENTING AND TREATING ACUTE KIDNEY INJURY | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2022251370-A1 | METHODS OF TREATING RETINAL VASCULOPATHIES | UNITY BIOTECHNOLOGY, INC. (US) | 2022-12-01 | — | — | WO | disclosed |
| CN-114805138-A | Prodrug of 6-diazo-5-oxo-L-norleucine, preparation method and application thereof | 中国科学院长春应用化学研究所 | 2022-07-29 | — | — | CN | disclosed |
| WO-2022056461-A1 | USE OF LONG NON-CODING RNAS IN MEDULLOBLASTOMA | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-03-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250177367-A1 | COMBINATION THERAPIES FOR MODULATION OF LIPID PRODUCTION | ACACB, SREBF2, FASN | L3MBTL1 2294/4885KMT2A 1381/4885POLB 3063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.